IMFINZI 50 mg/mL concentrate for solution for infusion. clinical trials
8 indexed studies · 0 currently recruiting
- Ongoing, recruitingTherapeutic exploratory (Phase II)
Thoracic Radiotherapy plus Durvalumab in Elderly and/or frail NSCLC stage III patients unfit for chemotherapy - Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy
This study looks at a new way to treat lung cancer for older or frailer patients. It combines a special type of radiation therapy with a drug called durvalumab (Imfinzi). The aim is to see if this treatment is safe and effective in shrinking tumors in people who can't have standard chemotherapy.
For: unresectable stage III NSCLC (Non–small-cell lung cancer)Germany - AuthorisedTherapeutic exploratory (Phase II)
An Open-label, Single-arm, Global Study of Perioperative Durvalumab With Cisplatin-based Neoadjuvant Chemotherapy in Patients With Muscle-Invasive Bladder Cancer (NIAGARA-2)
This study looks at a new treatment called Durvalumab (IMFINZI) combined with chemotherapy before surgery for bladder cancer. Researchers want to see if this combination causes any serious side effects and how well it works in patients with muscle-invasive bladder cancer.
For: Patients With Muscle-Invasive Bladder CancerItaly · Spain · France - Ongoing, recruitingPhase I and Phase II (Integrated)- Bioequivalence Study
MOVIE_A phase I/II basket trial evaluating a combination of Metronomic Oral Vinorelbine plus anti-PD-L1/anti-CTLA4 ImmunothErapy in patients with advanced solid tumours.
This study looks at a new combination treatment for advanced cancers. It combines a low, regular dose of vinorelbine (a chemotherapy drug) with two immunotherapy drugs (durvalumab and tremelimumab), aiming to find the safest dose and see how well it works.
For: Patients with locally advanced or metastatic solid tumoursFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A phase II trial of radiotherapy-durvalumab without prophylactic neck irradiation in squamous cell carcinoma of the head and neck (REWRITe)
This study is looking at a new way to treat head and neck cancer. It combines standard radiotherapy with a new drug called durvalumab, and aims to see if we can reduce the need for surgery in the neck, while still controlling the cancer.
For: Untreated squamous cell carcinoma of the head and neckFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
IFCT-1802 SAVIMMUNE A phase II single-arm trial evaluating safety and efficacy of Durvalumab in ECOG Performance Status 2-3, treatment-naive, patients with stage IV Non-Small Cell Lung Cancer (NSCLC) and high PD-L1 tumor expression
This study looks at a new cancer treatment called durvalumab (Imfinzi) for people with a type of advanced lung cancer. It aims to see how safe the treatment is and if it helps people feel better. It focuses on patients who are quite unwell at the start.
For: Non small cell lung cancer, Poor general statusFrance - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase II, Non-comparative, Open label, Multi-centre, International Study of MEDI4736, in Patients with Locally Advanced or Metastatic Non‑Small Cell Lung Cancer (Stage IIIB-IV) who have received at least Two Prior Systemic Treatment Regimens Including One Platinum-based Chemotherapy Regimen (ATLANTIC)
This study is looking at a new medicine called IMFINZI for people in the UK with advanced lung cancer who have already had at least two different treatments. It wants to see how well the medicine shrinks tumours and helps people live longer, while also checking for any side effects.
For: Locally Advanced or Metastatic Non-Small Cell Lung Cancer (Stage IIIBIV)Belgium - Ongoing, recruitingPhase I and Phase II (Integrated)- Other
A phase I/II multicenter trial evaluating the association of hypofractionated stereotactic radiation therapy and the anti-PD-L1 Durvalumab (Medi4736) for patients with recurrent glioblastoma
This study looks at combining a new type of radiation therapy with a drug called Durvalumab (Imfinzi) for people with a brain tumour called glioblastoma that has come back. It aims to see if this treatment is safe and if it helps people live longer.
For: Recurrent glioblastoma.France - AuthorisedTherapeutic exploratory (Phase II)
Phase II, clinical trial, to evaluate OS in two cohorts in relapsed stage III non-small-cell lung cancer (NSCLC) pretreated with chemoradiotherapy and durvalumab
This study is looking at a new treatment called IMFINZI for advanced lung cancer. It wants to see if IMFINZI can help people live longer, especially those whose cancer has come back after other treatments. The study is also checking if the treatment is safe and how well it works.
For: NSCLC non-small cell lung cancerItaly